On the occasion of World Haemophilia Day, the RHU TIPITCH project would like to highlight a population that is still too often excluded from clinical studies: patients at high haemorrhagic risk.

This includes in particular:

  • people living with haemophilia or other genetic coagulation disorders,
  • as well as certain patients receiving anticoagulant therapy.

Although these profiles account for around 15% of intracerebral haemorrhages, they have historically been under‑represented in research, due to the complexity and risks involved.

TIPITCH: addressing this challenge head‑on

Within RHU TIPITCH, a dedicated work package (WP2) directly tackles this issue.
Its objective is to better understand haematoma formation in these specific contexts and to safely promote haematoma evacuation in the patients at highest risk.

To achieve this, the teams:

  • use blood samples to model haematomas in the laboratory,
  • analyse the biological mechanisms specific to these patients,
  • and test innovative approaches, with the aim of developing safer and more appropriate treatments.

A major milestone reached

A key step has recently been achieved: the clinical trial arising from this work began on 2 March.

Since its launch, 40 participants have already been included, clearly illustrating the project’s inclusive ambition:

  • 1 healthy volunteer
  • 10 patients receiving anticoagulant therapy
  • 20 patients receiving antiplatelet therapy
  • 3 patients with von Willebrand disease
  • 6 patients with haemophilia (3 with haemophilia A and 3 with haemophilia B)

These are profiles that have historically been excluded from clinical trials and are now fully integrated into research — marking a tangible step towards truly inclusive medicine.

Also worth (re)discovering

Our video “TIPITCH in 2 minutes”, in which Prof Annabelle Dupont (Lille University Hospital) presents this key module, co‑led with Prof Sophie Susen, and outlines the foundations of this innovative therapeutic strategy.

On this World Haemophilia Day, TIPITCH reaffirms a strong conviction:
research must also — and above all — address the needs of the most vulnerable patients.